Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
6
|
| pubmed:dateCreated |
1998-1-14
|
| pubmed:abstractText |
Hepatocyte growth factor (HGF) is a humoral mediator of epithelial-mesenchymal interactions, acting on a variety of epithelial cells as mitogen, motogen, and morphogen. Exogenous HGF acts as a hepatotrophic factor and a renotrophic factor during experimental injury. To investigate whether HGF has a pulmotrophic function, human recombinant HGF was administered to C57BL/6 mice with severe lung injury by bleomycin (BLM). Low dose simultaneous and continuous administration of HGF (50 micrograms/mouse/7 d) with BLM (100 mg/mouse/7 d) repressed fibrotic morphological changes at 2 and 4 wk. Ashcroft score showed a significant difference in lung fibrosis with and without HGF at 4 wk (3.7 +/- 0.4 versus 4.9 +/- 0.3, p < 0.05). Furthermore, either simultaneous or delayed administration of high dose HGF (280 micrograms/mouse/14 d) equally repressed fibrotic changes by BLM when examined at 4 wk (Ashcroft score: 2.6 +/- 0.4 and 2.4 +/- 0.2 versus 4.1 +/- 0.2, p < 0.01). Hydroxyproline content in the lungs was significantly lower in mice with either simultaneous or delayed administration of high dose HGF as compared to those administered BLM alone (121.8 +/- 8.1% and 113.2 +/- 6.2% versus 162.7 +/- 4.6%, p < 0.001). These findings indicate that exogenous HGF acts as a pulmotrophic factor in vivo and prevents the progression of BLM-induced lung injury when administered in either a simultaneous or delayed fashion. HGF may be a potent candidate to prevent or treat lung fibrosis.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Dec
|
| pubmed:issn |
1073-449X
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
156
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1937-44
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:9412578-Animals,
pubmed-meshheading:9412578-Bleomycin,
pubmed-meshheading:9412578-Drug Administration Schedule,
pubmed-meshheading:9412578-Female,
pubmed-meshheading:9412578-Hepatocyte Growth Factor,
pubmed-meshheading:9412578-Lung,
pubmed-meshheading:9412578-Mice,
pubmed-meshheading:9412578-Mice, Inbred C57BL,
pubmed-meshheading:9412578-Recombinant Proteins,
pubmed-meshheading:9412578-Respiratory Distress Syndrome, Adult
|
| pubmed:year |
1997
|
| pubmed:articleTitle |
Simultaneous or delayed administration of hepatocyte growth factor equally represses the fibrotic changes in murine lung injury induced by bleomycin. A morphologic study.
|
| pubmed:affiliation |
Department of Respiratory Oncology and Molecular Medicine, Tohoku University, Sendai, Japan. yaesan@idac.tohoku.ac.jp
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|